Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced participation in the UBS Genomics 2.0 and Medtech Innovations Virtual Summit on August 11, 2020. The management team will engage in a fireside chat at 11:00 a.m. Pacific Time, which will also be available via webcast on the company's website. Adaptive Biotechnologies focuses on leveraging the adaptive immune system to create diagnostics and treatments for diseases, including cancer and autoimmune conditions. The company aims to develop tailored immune-driven clinical products, backed by a robust clinical pipeline and two commercial offerings.
- None.
- None.
SEATTLE, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming UBS Genomics 2.0 and Medtech Innovations Virtual Summit.
Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, August 11th at 11:00 a.m. Pactific Time / 2:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.
About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com and follow us on www.twitter.com/adaptivebiotech.
Investor Contact:
Carrie Mendivil
investors@adaptivebiotech.com
Media Contact:
Beth Keshishian
media@adaptivebiotech.com
FAQ
What event is Adaptive Biotechnologies participating in on August 11, 2020?
At what time will Adaptive Biotechnologies' fireside chat occur?
Where can I access the webcast of the Adaptive Biotechnologies presentation?
What products does Adaptive Biotechnologies focus on?
What is the stock symbol for Adaptive Biotechnologies?
